TOPICAL CYCLOSPORINE A 2% IN MANAGEMENT OF ENDOTHELIAL CORNEAL ALLOGRAFT REJECTION

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

NEJABAT M.; KHOUSHGHADAM J.; KATBAB A.; KHOUSHNIAT H.; JAHADI H.R.; MOVAHEDAN H.; SALOUTI R.

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: BINA Year:2005 | Volume:10 | Issue:5 (41) Page(s): 613-619

Download Full-Text

Persian Verion

View:

5,115

Download:

Cites:

Information Journal Paper

Title

TOPICAL CYCLOSPORINE A 2% IN MANAGEMENT OF ENDOTHELIAL CORNEAL ALLOGRAFT REJECTION

Author(s)

Keywords

CYCLOSPORINE AQ3

PENETRATING KERATOPLASTYQ3

GRAFT REJECTIONQ3

Abstract

Purpose: To determine whether adding 2% topical cyclosporine (CSA) to local and systemic steroids in treatment of endothelial corneal allograft rejection improves the outcome. Methods: A prospective randomized treatment trial was carried out on 40 consecutive corneal graft recipients, presenting with the first episode of endothelial GRAFT REJECTION in two groups. Group one (20 patients) received topical steroid eye drops and oral prednisolone (1 mg/kg). Group two (20 patients) received the same topical and systemic therapy plus 2% cyc1osporine eye drops. The patients were followed up for three months and their clinical outcomes were evaluated by the rates and time for reversal of rejection. Results: In group one, 14 (70%) cases had total reversal of GRAFT REJECTION episode which started within a mean period of three days. but in the CSA group, it occurred in 18 (90%) cases which started within a mean period of 1.5 days (P=0.21).Among patients who sought treatment early (< 6 days). survival rates were 85% and 100%, respectively (P=0.2). In high risk patients, the rejection reversal rate was 66% in CSA group and 25% in the control group (P=0.5). Conclusion: Addition of 2% CSA eye drop to topical and systemic steroids may improve the rates of GRAFT REJECTION reversal. It may also decrease the interval between initiation of treatment and improvement of clinical signs.

Cites

No record.

References

CORNEAL GRAFT REJECTION: MECHANISM, CLINICAL MANIFESTATIONS, DIAGNOSIS, AND TREATMENT

Cite

APA: Copy

NEJABAT, M., KHOUSHGHADAM, J., KATBAB, A., KHOUSHNIAT, H., JAHADI, H.R., MOVAHEDAN, H., & SALOUTI, R.. (2005). TOPICAL CYCLOSPORINE A 2% IN MANAGEMENT OF ENDOTHELIAL CORNEAL ALLOGRAFT REJECTION. BINA, 10(5 (41)), 613-619. SID. https://sid.ir/paper/42974/en

Vancouver: Copy

NEJABAT M., KHOUSHGHADAM J., KATBAB A., KHOUSHNIAT H., JAHADI H.R., MOVAHEDAN H., SALOUTI R.. TOPICAL CYCLOSPORINE A 2% IN MANAGEMENT OF ENDOTHELIAL CORNEAL ALLOGRAFT REJECTION. BINA[Internet]. 2005;10(5 (41)):613-619. Available from: https://sid.ir/paper/42974/en

IEEE: Copy

M. NEJABAT, J. KHOUSHGHADAM, A. KATBAB, H. KHOUSHNIAT, H.R. JAHADI, H. MOVAHEDAN, and R. SALOUTI, “TOPICAL CYCLOSPORINE A 2% IN MANAGEMENT OF ENDOTHELIAL CORNEAL ALLOGRAFT REJECTION,” BINA, vol. 10, no. 5 (41), pp. 613–619, 2005, [Online]. Available: https://sid.ir/paper/42974/en

Related Journal Papers